STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence

CG Oncology's bladder cancer immunotherapy reduced risk of tumor recurrence by 68% — results that may change how physicians treat certain patients.
This is a brief. The reporting belongs to STAT — read the complete story, with full context and credits, at the source.
Read the full story at STAT ↗statnews.com
More from the Health desk
Just in

STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions

Pope Leo wraps up South America tour that tested recovery from cancer surgery

Women's criminal records wiped for abortion offences
